Alshaker, H., Wang, Q., Kawano, Y., Arafat, T., Böhler, T., Winkler, M., . . . Pchejetski, D. (2016). Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1. Oncotarget.

Alshaker, Heba, Qi Wang, Yoshiaki Kawano, Tawfiq Arafat, Torsten Böhler, Mathias Winkler, Colin Cooper, e Dmitri Pchejetski. "Everolimus (RAD001) Sensitizes Prostate Cancer Cells to Docetaxel By Down-regulation of HIF-1α and Sphingosine Kinase 1." Oncotarget 2016.

Alshaker, Heba, et al. "Everolimus (RAD001) Sensitizes Prostate Cancer Cells to Docetaxel By Down-regulation of HIF-1α and Sphingosine Kinase 1." Oncotarget 2016.